Literature DB >> 29420822

Bifactor Modeling of the Positive and Negative Syndrome Scale: Generalized Psychosis Spans Schizoaffective, Bipolar, and Schizophrenia Diagnoses.

Ariana E Anderson1,2, Stephen Marder1, Steven P Reise3, Adam Savitz4, Giacomo Salvadore4, Dong Jing Fu4, Qingqin Li4, Ibrahim Turkoz4, Carol Han1, Robert M Bilder1,3.   

Abstract

Objective: Common genetic variation spans schizophrenia, schizoaffective and bipolar disorders, but historically, these syndromes have been distinguished categorically. A symptom dimension shared across these syndromes, if such a general factor exists, might provide a clearer target for understanding and treating mental illnesses that share core biological bases. Method: We tested the hypothesis that a bifactor model of the Positive and Negative Syndrome Scale (PANSS), containing 1 general factor and 5 specific factors (positive, negative, disorganized, excited, anxiety), explains the cross-diagnostic structure of symptoms better than the traditional 5-factor model, and examined the extent to which a general factor reflects the overall severity of symptoms spanning diagnoses in 5094 total patients with a diagnosis of schizophrenia, schizoaffective, and bipolar disorder.
Results: The bifactor model provided superior fit across diagnoses, and was closer to the "true" model, compared to the traditional 5-factor model (Vuong test; P < .001). The general factor included high loadings on 28 of the 30 PANSS items, omitting symptoms associated with the excitement and anxiety/depression domains. The general factor had highest total loadings on symptoms that are often associated with the positive and disorganization syndromes, but there were also substantial loadings on the negative syndrome thus leading to the interpretation of this factor as reflecting generalized psychosis. Conclusions: A bifactor model derived from the PANSS can provide a stronger framework for measuring cross-diagnostic psychopathology than a 5-factor model, and includes a generalized psychosis dimension shared at least across schizophrenia, schizoaffective, and bipolar disorder.

Entities:  

Mesh:

Year:  2018        PMID: 29420822      PMCID: PMC6192503          DOI: 10.1093/schbul/sbx163

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  47 in total

1.  A shrinkage approach to large-scale covariance matrix estimation and implications for functional genomics.

Authors:  Juliane Schäfer; Korbinian Strimmer
Journal:  Stat Appl Genet Mol Biol       Date:  2005-11-14

2.  Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study.

Authors:  Srihari Gopal; David W Hough; Haiyan Xu; Julia M Lull; Cristiana Gassmann-Mayer; Bart M Remmerie; Marielle H Eerdekens; David W Brown
Journal:  Int Clin Psychopharmacol       Date:  2010-09       Impact factor: 1.659

3.  Paliperidone extended-release in schizoaffective disorder: a randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizers.

Authors:  Carla M Canuso; Nina Schooler; Jennifer Carothers; Ibrahim Turkoz; Colette Kosik-Gonzalez; Cynthia A Bossie; David Walling; Jean-Pierre Lindenmayer
Journal:  J Clin Psychopharmacol       Date:  2010-10       Impact factor: 3.153

Review 4.  Is the PANSS used correctly? a systematic review.

Authors:  Michael Obermeier; Rebecca Schennach-Wolff; Sebastian Meyer; Hans-Jürgen Möller; Michael Riedel; Daniela Krause; Florian Seemüller
Journal:  BMC Psychiatry       Date:  2011-07-18       Impact factor: 3.630

5.  Invited Paper: The Rediscovery of Bifactor Measurement Models.

Authors:  Steven P Reise
Journal:  Multivariate Behav Res       Date:  2012-09-01       Impact factor: 5.923

6.  Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study.

Authors:  Michelle Kramer; Robert Litman; David Hough; Rosanne Lane; Pilar Lim; Yanning Liu; Mariëlle Eerdekens
Journal:  Int J Neuropsychopharmacol       Date:  2009-11-27       Impact factor: 5.176

7.  Five factor model of schizophrenia: replication across samples.

Authors:  J P Lindenmayer; S Grochowski; R B Hyman
Journal:  Schizophr Res       Date:  1995-02       Impact factor: 4.939

8.  The symptoms of chronic schizophrenia. A re-examination of the positive-negative dichotomy.

Authors:  P F Liddle
Journal:  Br J Psychiatry       Date:  1987-08       Impact factor: 9.319

9.  Evaluation of the validity and utility of a transdiagnostic psychosis dimension encompassing schizophrenia and bipolar disorder.

Authors:  Ulrich Reininghaus; Jan R Böhnke; Georgina Hosang; Anne Farmer; Tom Burns; Peter McGuffin; Richard P Bentall
Journal:  Br J Psychiatry       Date:  2016-03-17       Impact factor: 9.319

10.  Toward the future of psychiatric diagnosis: the seven pillars of RDoC.

Authors:  Bruce N Cuthbert; Thomas R Insel
Journal:  BMC Med       Date:  2013-05-14       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.